Chelation of Mitochondrial Iron as an Antiparasitic Strategy.

chelation iron mitochondria parasites protists

Journal

ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580

Informations de publication

Date de publication:
30 Jan 2024
Historique:
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 30 1 2024
Statut: aheadofprint

Résumé

Iron, as an essential micronutrient, plays a crucial role in host-pathogen interactions. In order to limit the growth of the pathogen, a common strategy of innate immunity includes withdrawing available iron to interfere with the cellular processes of the microorganism. Against that, unicellular parasites have developed powerful strategies to scavenge iron, despite the effort of the host. Iron-sequestering compounds, such as the approved and potent chelator deferoxamine (DFO), are considered a viable option for therapeutic intervention. Since iron is heavily utilized in the mitochondrion, targeting iron chelators in this organelle could constitute an effective therapeutic strategy. This work presents mitochondrially targeted DFO, mitoDFO, as a candidate against a range of unicellular parasites with promising in vitro efficiency. Intracellular

Identifiants

pubmed: 38287902
doi: 10.1021/acsinfecdis.3c00529
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Dominik Arbon (D)

Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.

Jan Mach (J)

Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.

Aneta Čadková (A)

Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.

Anna Sipkova (A)

Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.

Jan Stursa (J)

Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic.
Laboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic.

Kristýna Klanicová (K)

Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic.
Department of Organic Chemistry, Faculty of Science, Charles University, Prague 128 00, Czech Republic.

Marta Machado (M)

Graduate Program in Areas of Basic and Applied Biology, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto 4050-313, Portugal.
Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany.

Markus Ganter (M)

Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany.

Viktoriya Levytska (V)

Institute of Parasitology, Biology Centre, Academy of Sciences of the Czech Republic, Branišovská 1160/31, České Budějovice 37005, Czech Republic.

Daniel Sojka (D)

Institute of Parasitology, Biology Centre, Academy of Sciences of the Czech Republic, Branišovská 1160/31, České Budějovice 37005, Czech Republic.

Jaroslav Truksa (J)

Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic.

Lukáš Werner (L)

Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic.
Laboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic.

Robert Sutak (R)

Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic.

Classifications MeSH